[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-retatrutide-liver-damage-myths-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":7,"cat":9,"icon":10,"accent":11,"date":12,"dateLabel":13,"read":14,"author":15,"image":16,"body":17,"_type":2362,"_id":2363,"_source":2364,"_file":2365,"_stem":2366,"_extension":2367},"\u002Fblog\u002Fzh\u002Fretatrutide-liver-damage-myths","zh",false,"","瑞它鲁肽伤肝？一次彻底的事实核查","事实核查","tabler:microscope","#F2A93B","2026-06-27","2026年6月","20 min","myPeptides Team","\u002Fassets\u002Freta_hero.png",{"type":18,"children":19,"toc":2340},"root",[20,122,128,133,300,305,311,316,321,330,381,400,406,438,457,463,468,476,512,538,544,549,557,577,635,641,646,654,680,685,690,733,738,743,748,752,757,762,768,788,809,814,835,870,876,909,949,955,1008,1029,1064,1082,1175,1192,1286,1291,1297,1316,1363,1369,1381,1406,1412,1444,1450,1464,1469,1494,1522,1527],{"type":21,"tag":22,"props":23,"children":24},"element","disclaimer",{},[25,38,70,80,99,114],{"type":21,"tag":26,"props":27,"children":28},"p",{},[29,36],{"type":21,"tag":30,"props":31,"children":32},"em",{},[33],{"type":34,"value":35},"text","本文属于观点表达与科学评论——不是医疗建议，除有出处支撑的内容外，也不构成对任何人的事实陈述。",{"type":34,"value":37}," 出于公共利益和公允评论的立场，本文讨论的是一位公众人物选择向大量受众发布的医疗类说法。",{"type":21,"tag":26,"props":39,"children":40},{},[41,47,49,54,56,61,63,68],{"type":21,"tag":42,"props":43,"children":44},"strong",{},[45],{"type":34,"value":46},"事实与观点之分。",{"type":34,"value":48}," 凡是我们陈述可查证的事实之处——执业资质状态、企业归属、公开记录和视频里的原话——我们都附上一手出处，方便你自己去核对。凡是我们标明为",{"type":21,"tag":30,"props":50,"children":51},{},[52],{"type":34,"value":53},"评估",{"type":34,"value":55},"、",{"type":21,"tag":30,"props":57,"children":58},{},[59],{"type":34,"value":60},"对数据的解读",{"type":34,"value":62},"或",{"type":21,"tag":30,"props":64,"children":65},{},[66],{"type":34,"value":67},"我们的看法",{"type":34,"value":69},"的地方，都是针对公开言论的观点与公允评论。我们并不声称掌握任何人的私人动机；凡涉及动机或效果之处，我们说的是我们所见，而非既定事实。",{"type":21,"tag":26,"props":71,"children":72},{},[73,78],{"type":21,"tag":42,"props":74,"children":75},{},[76],{"type":34,"value":77},"出处可能并不完整。",{"type":34,"value":79}," 本文所有信息均取自公开来源，并本着善意、以我们撰稿时所掌握的最好认知如实呈现。公开记录和第三方报道可能不完整、可能有变、也可能被后续信息取代；我们或许遗漏了某些背景，在细节上也可能出错。",{"type":21,"tag":26,"props":81,"children":82},{},[83,88,90,97],{"type":21,"tag":42,"props":84,"children":85},{},[86],{"type":34,"value":87},"答辩与更正权。",{"type":34,"value":89}," 如果你在本文中被提及，且认为任何事实陈述有误或已过时——或者你希望补充自己的立场——请通过我们的",{"type":21,"tag":91,"props":92,"children":94},"a",{"href":93},"\u002Flegal-notice",[95],{"type":34,"value":96},"法律声明",{"type":34,"value":98},"与我们联系，我们会在合理范围内审阅并更正或更新文章。我们欢迎有据可查的更正。",{"type":21,"tag":26,"props":100,"children":101},{},[102,107,109],{"type":21,"tag":42,"props":103,"children":104},{},[105],{"type":34,"value":106},"不是医疗建议——也不是在推荐你去用任何东西。",{"type":34,"value":108}," 本文没有任何一句是在告诉你该拿自己的身体怎么办，也没有任何一句是在背书或指导你去获取、给药或使用瑞它鲁肽或其他任何物质——其中好几种还是在研药物，在许多地方并未获批用于人体。我们引用的试验数字描述的是已发表研究里报告的结果；它们不是任何疗效的承诺，也不是给药指导。如果你正在考虑或正在使用这些物质中的任何一种，",{"type":21,"tag":42,"props":110,"children":111},{},[112],{"type":34,"value":113},"在照着网上（无论这里还是别处）读到的东西行动之前，先去当面找一位你最不那么信不过的医生。",{"type":21,"tag":26,"props":115,"children":116},{},[117],{"type":21,"tag":30,"props":118,"children":119},{},[120],{"type":34,"value":121},"最后更新：2026年6月27日。本文为观点与评论，可能随着新信息出现而修订。",{"type":21,"tag":123,"props":124,"children":126},"h2",{"id":125},"一句话总结",[127],{"type":34,"value":125},{"type":21,"tag":26,"props":129,"children":130},{},[131],{"type":34,"value":132},"一段45分钟、标题为*《瑞它鲁肽大剂量 vs 微剂量：哪种更伤你的肝？》*的视频宣称，除非你照着某套特定的给药方案来，否则瑞它鲁肽会悄悄损伤你的肝脏和胰腺——而讲这套话的人，随后就把这套方案连同肽本身一起卖给你。我们查证了一番。长话短说：",{"type":21,"tag":134,"props":135,"children":136},"ul",{},[137,174,224,249,281],{"type":21,"tag":138,"props":139,"children":140},"li",{},[141,146,148,153,155,163,165,172],{"type":21,"tag":42,"props":142,"children":143},{},[144],{"type":34,"value":145},"传话的人。",{"type":34,"value":147}," “Trevor Bachmeyer 博士”并不是医生。他曾是脊椎按摩师，连这个执照都已经没了：加州执照（DC 29377）",{"type":21,"tag":42,"props":149,"children":150},{},[151],{"type":34,"value":152},"已于2020年7月8日起被吊销",{"type":34,"value":154},"，这一点",{"type":21,"tag":91,"props":156,"children":160},{"href":157,"rel":158},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fabout_us\u002Fmeetings\u002F20201029_materials.pdf",[159],"nofollow",[161],{"type":34,"value":162},"加州脊椎按摩师考核委员会",{"type":34,"value":164},"有案可查。同一段视频还把观众导流到他的付费辅导，以及他自己的科研肽商店 ",{"type":21,"tag":91,"props":166,"children":169},{"href":167,"rel":168},"https:\u002F\u002Felitebiogenix.com\u002F",[159],[170],{"type":34,"value":171},"EliteBiogenix",{"type":34,"value":173},"。",{"type":21,"tag":138,"props":175,"children":176},{},[177,182,184,189,191,196,198,205,207,214,215,222],{"type":21,"tag":42,"props":178,"children":179},{},[180],{"type":34,"value":181},"“胰高血糖素让脂肪淹没全身。”",{"type":34,"value":183}," 误导。在人体内，生理浓度的胰高血糖素",{"type":21,"tag":42,"props":185,"children":186},{},[187],{"type":34,"value":188},"并不会",{"type":34,"value":190},"直接分解身体（白色脂肪组织）里的脂肪——它驱动的是",{"type":21,"tag":30,"props":192,"children":193},{},[194],{"type":34,"value":195},"肝脏内部",{"type":34,"value":197},"的脂肪氧化（",{"type":21,"tag":91,"props":199,"children":202},{"href":200,"rel":201},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32132708\u002F",[159],[203],{"type":34,"value":204},"Perry 等，Nature 2020",{"type":34,"value":206},"；",{"type":21,"tag":91,"props":208,"children":211},{"href":209,"rel":210},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9576180\u002F",[159],[212],{"type":34,"value":213},"Vasileva 等，2022",{"type":34,"value":206},{"type":21,"tag":91,"props":216,"children":219},{"href":217,"rel":218},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11344211\u002F",[159],[220],{"type":34,"value":221},"Gravholt 等，2001",{"type":34,"value":223},"）。",{"type":21,"tag":138,"props":225,"children":226},{},[227,232,234,239,241,248],{"type":21,"tag":42,"props":228,"children":229},{},[230],{"type":34,"value":231},"“脂肪酶升高意味着你的胰腺在衰竭。”",{"type":34,"value":233}," 基本是错的。轻度、无症状的酶升高很常见，也无害；大型试验数据显示",{"type":21,"tag":42,"props":235,"children":236},{},[237],{"type":34,"value":238},"急性胰腺炎并没有增加",{"type":34,"value":240},"（",{"type":21,"tag":91,"props":242,"children":245},{"href":243,"rel":244},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28476871\u002F",[159],[246],{"type":34,"value":247},"Steinberg 等，Diabetes Care 2017",{"type":34,"value":223},{"type":21,"tag":138,"props":250,"children":251},{},[252,257,259,264,266,271,272,279],{"type":21,"tag":42,"props":253,"children":254},{},[255],{"type":34,"value":256},"“瑞它鲁肽让肝脏不堪重负、受到损伤。”",{"type":34,"value":258}," 数据恰恰相反。在二期肝脂肪试验里，它",{"type":21,"tag":42,"props":260,"children":261},{},[262],{"type":34,"value":263},"让肝脏脂肪最多减少了86%",{"type":34,"value":265},"，而且",{"type":21,"tag":42,"props":267,"children":268},{},[269],{"type":34,"value":270},"用最高剂量的患者中约93%的人肝脂肪恢复了正常",{"type":34,"value":240},{"type":21,"tag":91,"props":273,"children":276},{"href":274,"rel":275},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11271400\u002F",[159],[277],{"type":34,"value":278},"Sanyal 等，Nature Medicine 2024",{"type":34,"value":280},"）。瑞它鲁肽恰恰是作为脂肪肝的治疗药物来开发的。",{"type":21,"tag":138,"props":282,"children":283},{},[284,289,291,298],{"type":21,"tag":42,"props":285,"children":286},{},[287],{"type":34,"value":288},"他说对的部分。",{"type":34,"value":290}," 有两点：别为了一个孤立的脂肪酶数值就慌慌张张停药；快速减重确实会赔上肌肉（",{"type":21,"tag":91,"props":292,"children":295},{"href":293,"rel":294},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12471476\u002F",[159],[296],{"type":34,"value":297},"Koceva 等，2025",{"type":34,"value":299},"）。有道理的观点，被裹进了一套站不住脚的吓人叙事里。",{"type":21,"tag":26,"props":301,"children":302},{},[303],{"type":34,"value":304},"更完整的图景，以及上面每一句背后的科学，都在下文。文末的深挖是一份带出处的入门读物，讲的是整个这一类药——写出来就是让你能核对我们，而不只是相信我们。",{"type":21,"tag":306,"props":307,"children":310},"youtube",{"id":308,"title":309},"gb-XEtsMr-w","The video this article examines — Bachmeyer on retatrutide dosing",[],{"type":21,"tag":123,"props":312,"children":314},{"id":313},"是谁在这么说",[315],{"type":34,"value":313},{"type":21,"tag":26,"props":317,"children":318},{},[319],{"type":34,"value":320},"在看科学之前，先看来源。他给自己贴的标签是“Trevor Bachmeyer 博士，斯巴达人”和“全球第一健康权威”，面对的是数十万观众。有两个可查证的事实很关键。",{"type":21,"tag":26,"props":322,"children":323},{},[324],{"type":21,"tag":325,"props":326,"children":329},"img",{"alt":327,"src":328},"健康恐慌是如何被一步步引向商品销售的","\u002Fassets\u002Freta_funnel.png",[],{"type":21,"tag":26,"props":331,"children":332},{},[333,335,340,342,347,349,354,356,362,363,370,372,379],{"type":34,"value":334},"第一，",{"type":21,"tag":42,"props":336,"children":337},{},[338],{"type":34,"value":339},"他不是医生。",{"type":34,"value":341}," 他曾是",{"type":21,"tag":42,"props":343,"children":344},{},[345],{"type":34,"value":346},"脊椎按摩师",{"type":34,"value":348},"，而连这个执照都没了：加州执照 DC 29377 ",{"type":21,"tag":42,"props":350,"children":351},{},[352],{"type":34,"value":353},"已于2020年7月8日起被加州脊椎按摩师考核委员会吊销",{"type":34,"value":355},"。这一处分在委员会自己的文件里有据可查（",{"type":21,"tag":91,"props":357,"children":359},{"href":157,"rel":358},[159],[360],{"type":34,"value":361},"2020年10月29日会议材料",{"type":34,"value":206},{"type":21,"tag":91,"props":364,"children":367},{"href":365,"rel":366},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fenforcement\u002Factions.shtml",[159],[368],{"type":34,"value":369},"最终纪律处分",{"type":34,"value":371},"），也可以通过州里的",{"type":21,"tag":91,"props":373,"children":376},{"href":374,"rel":375},"https:\u002F\u002Fsearch.dca.ca.gov\u002F",[159],[377],{"type":34,"value":378},"执照查询",{"type":34,"value":380},"自行核实——读者可以查阅所附记录，了解具体的认定内容。他至今仍以“博士”自居，在我们看来，这种用法会诱导读者以为他持有一份其实并不具备的现行医疗资质。",{"type":21,"tag":26,"props":382,"children":383},{},[384,386,391,393,398],{"type":34,"value":385},"第二，",{"type":21,"tag":42,"props":387,"children":388},{},[389],{"type":34,"value":390},"他卖的正是他自己在建议的那个东西。",{"type":34,"value":392}," 视频把观众引向一个付费的“黑卡”辅导会员，以及他的商店 ",{"type":21,"tag":91,"props":394,"children":396},{"href":167,"rel":395},[159],[397],{"type":34,"value":171},{"type":34,"value":399},"——那里卖的是科研肽和 SARM，标注“仅供体外研究”。所以，那个警告你“瑞它鲁肽会伤你，除非你剂量用对”的人，同时也在卖那套剂量指导和那些肽。这本身并不能一票否决他——但这恰恰是一个谨慎的观众应当记在心里的利益冲突，也正是本文存在的理由。",{"type":21,"tag":123,"props":401,"children":403},{"id":402},"平心而论他到底在主张什么",[404],{"type":34,"value":405},"平心而论，他到底在主张什么",{"type":21,"tag":26,"props":407,"children":408},{},[409,411,416,418,423,425,429,431,436],{"type":34,"value":410},"要把他树成一个稻草人来打很容易，所以我们要说得准确。他自己的视频简介写道：",{"type":21,"tag":30,"props":412,"children":413},{},[414],{"type":34,"value":415},"“瑞它鲁肽本身并不直接造成肝脏或胰腺损伤；是不负责任的给药和糟糕的监测造成了生物学损伤。”",{"type":34,"value":417}," 他的章节列表是*“胰高血糖素脂肪洪流 → 胰腺超载 → 脂肪肝级联 → 胰岛素抵抗漩涡”",{"type":21,"tag":30,"props":419,"children":420},{},[421],{"type":34,"value":422},"，接着话锋一转，转到",{"type":34,"value":424},"“损伤控制方案”",{"type":21,"tag":30,"props":426,"children":427},{},[428],{"type":34,"value":55},{"type":34,"value":430},"“安全给药规则”",{"type":21,"tag":30,"props":432,"children":433},{},[434],{"type":34,"value":435},"和",{"type":34,"value":437},"“负责任地使用”*。",{"type":21,"tag":26,"props":439,"children":440},{},[441,443,448,450,455],{"type":34,"value":442},"所以他的论点",{"type":21,"tag":42,"props":444,"children":445},{},[446],{"type":34,"value":447},"并不是",{"type":34,"value":449},"“这药是毒药，别碰”。而是“这药会伤你，",{"type":21,"tag":30,"props":451,"children":452},{},[453],{"type":34,"value":454},"除非你按我的方式给药",{"type":34,"value":456},"”。这更微妙、听起来更可信、也远比前者好卖——而这正是我们要核查的。问题不在于他编造假研究。而在于他用一堆真实的术语，搭起了一台吓人的机器，可试验数据并不支持那个吓人的部分。",{"type":21,"tag":123,"props":458,"children":460},{"id":459},"说法一胰高血糖素脂肪洪流",[461],{"type":34,"value":462},"说法一：“胰高血糖素脂肪洪流”",{"type":21,"tag":26,"props":464,"children":465},{},[466],{"type":34,"value":467},"他这台机器的引擎，是瑞它鲁肽里的胰高血糖素成分：据说它会掀起一场脂肪的洪水——游离脂肪酸从你的身体脂肪里倾泻而出，把肝脏和胰腺给淹没。",{"type":21,"tag":26,"props":469,"children":470},{},[471],{"type":21,"tag":325,"props":472,"children":475},{"alt":473,"src":474},"胰高血糖素驱动的是肝脏里的脂肪氧化，而非身体脂肪","\u002Fassets\u002Freta_glucagon.png",[],{"type":21,"tag":26,"props":477,"children":478},{},[479,481,486,488,494,496,502,503,510],{"type":34,"value":480},"这是胰高血糖素生理学里最古老的一个误解。没错，胰高血糖素是一个强力的燃脂信号——",{"type":21,"tag":42,"props":482,"children":483},{},[484],{"type":34,"value":485},"但是在肝脏里，不是在你的身体脂肪里。",{"type":34,"value":487}," 胰高血糖素受体在肝细胞上密集表达，在人的脂肪细胞上却几乎不存在。当研究者专门把小鼠脂肪组织里的胰高血糖素受体敲除后，它们的脂肪代谢、体重、循环游离脂肪酸——什么都没变（",{"type":21,"tag":91,"props":489,"children":491},{"href":209,"rel":490},[159],[492],{"type":34,"value":493},"Vasileva 等，AJP-Endocrinology 2022",{"type":34,"value":495},"）。在人体里，把胰高血糖素升到生理水平，压根不会增加腹部脂肪的脂解（",{"type":21,"tag":91,"props":497,"children":499},{"href":217,"rel":498},[159],[500],{"type":34,"value":501},"Gravholt 等，JCEM 2001",{"type":34,"value":206},{"type":21,"tag":91,"props":504,"children":507},{"href":505,"rel":506},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F1991802\u002F",[159],[508],{"type":34,"value":509},"Jensen 等，JCEM 1991",{"type":34,"value":511},"）。脂解效应只有在试管里、在血液里根本达不到的超生理浓度下才会出现。",{"type":21,"tag":26,"props":513,"children":514},{},[515,517,521,523,528,529,536],{"type":34,"value":516},"胰高血糖素真正做的，是驱动",{"type":21,"tag":42,"props":518,"children":519},{},[520],{"type":34,"value":195},{"type":34,"value":522},"的脂肪氧化——通过 cAMP\u002FPKA 和钙通路激活肝脏的脂肪分解（",{"type":21,"tag":91,"props":524,"children":526},{"href":200,"rel":525},[159],[527],{"type":34,"value":204},{"type":34,"value":206},{"type":21,"tag":91,"props":530,"children":533},{"href":531,"rel":532},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F38300523\u002F",[159],[534],{"type":34,"value":535},"Kajani 等，Physiological Reviews 2024",{"type":34,"value":537},"）——并提高全身能量消耗。至于胰高血糖素“融化”你的肚子脂肪、再让它涌进你各个器官的画面，那是体外实验的假象，不是人体生理。他那场“洪水”的地基，从第一章就裂了。",{"type":21,"tag":123,"props":539,"children":541},{"id":540},"说法二胰腺超载",[542],{"type":34,"value":543},"说法二：胰腺“超载”",{"type":21,"tag":26,"props":545,"children":546},{},[547],{"type":34,"value":548},"接下来，他把脂肪酶升高当成你的胰腺正被逼向衰竭的证据。",{"type":21,"tag":26,"props":550,"children":551},{},[552],{"type":21,"tag":325,"props":553,"children":556},{"alt":554,"src":555},"轻度脂肪酶升高反映的是无害的酶渗漏，而不是胰腺被摧毁","\u002Fassets\u002Freta_pancreas.png",[],{"type":21,"tag":26,"props":558,"children":559},{},[560,562,567,569,576],{"type":34,"value":561},"平淡的真相是：在这一类药上，轻度、无症状的脂肪酶和淀粉酶升高",{"type":21,"tag":42,"props":563,"children":564},{},[565],{"type":34,"value":566},"很常见，而且通常无害",{"type":34,"value":568},"。这反映的是被刺激但依然完好的腺泡细胞往血里渗出一点点酶——一种生理性的“渗漏”，而不是器官在自我消化。我们甚至知道其中的受体机制：GLP-1 受体位于胰腺腺泡细胞上，会推动它们释放酶，这发生在健康组织里，不造成损伤（",{"type":21,"tag":91,"props":570,"children":573},{"href":571,"rel":572},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4698438\u002F",[159],[574],{"type":34,"value":575},"Hou…Williams 等，AJP-GI 2016",{"type":34,"value":223},{"type":21,"tag":26,"props":578,"children":579},{},[580,582,587,588,593,595,602,604,609,610,617,619,624,626,633],{"type":34,"value":581},"而那些硬终点指标令人放心。在大型利拉鲁肽试验项目里，淀粉酶和脂肪酶有轻度升高，",{"type":21,"tag":42,"props":583,"children":584},{},[585],{"type":34,"value":586},"却并不预示急性胰腺炎",{"type":34,"value":240},{"type":21,"tag":91,"props":589,"children":591},{"href":243,"rel":590},[159],[592],{"type":34,"value":247},{"type":34,"value":594},"）。一项2026年持续更新的系统综述（living systematic review），汇总了31项安慰剂对照试验、超过4万名患者，发现用药组与安慰剂组的胰腺炎发生率基本一模一样（比值比 ≈ 0.99）——不过平心而论，这一项目前还是",{"type":21,"tag":91,"props":596,"children":599},{"href":597,"rel":598},"https:\u002F\u002Fwww.medrxiv.org\u002Fcontent\u002F10.64898\u002F2026.03.19.26348844v1",[159],[600],{"type":34,"value":601},"预印本",{"type":34,"value":603},"，尚未经过同行评审。一项2024年的分析甚至报告，在高风险患者中，用 GLP-1 类药物后复发性胰腺炎发作",{"type":21,"tag":42,"props":605,"children":606},{},[607],{"type":34,"value":608},"更少",{"type":34,"value":240},{"type":21,"tag":91,"props":611,"children":614},{"href":612,"rel":613},"https:\u002F\u002Fwww.endocrine.org\u002Fnews-and-advocacy\u002Fnews-room\u002F2024\u002Fendo-2024-press-nassar",[159],[615],{"type":34,"value":616},"Nassar 等，ENDO 2024 —— 会议摘要",{"type":34,"value":618},"），可能是因为这些药物纠正了根本诱因。关键在于，急性胰腺炎是一个临床诊断——修订版亚特兰大标准要求同时满足真实的疼痛、脂肪酶超过正常上限三倍、",{"type":21,"tag":30,"props":620,"children":621},{},[622],{"type":34,"value":623},"以及",{"type":34,"value":625},"影像学证据（",{"type":21,"tag":91,"props":627,"children":630},{"href":628,"rel":629},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23100216\u002F",[159],[631],{"type":34,"value":632},"Banks 等，Gut 2013",{"type":34,"value":634},"）。光凭一个孤立的化验数值还不足以确诊，而从“你的脂肪酶升高了”直接跳到“你的胰腺正超载走向衰竭”，是没有依据的。",{"type":21,"tag":123,"props":636,"children":638},{"id":637},"说法三脂肪肝级联",[639],{"type":34,"value":640},"说法三：“脂肪肝级联”",{"type":21,"tag":26,"props":642,"children":643},{},[644],{"type":34,"value":645},"这是最核心的一处颠倒，也是最值得弄清楚的一处。",{"type":21,"tag":26,"props":647,"children":648},{},[649],{"type":21,"tag":325,"props":650,"children":653},{"alt":651,"src":652},"在临床试验中，瑞它鲁肽大幅降低肝脏脂肪","\u002Fassets\u002Freta_liverfat.png",[],{"type":21,"tag":26,"props":655,"children":656},{},[657,659,664,666,671,673,678],{"type":34,"value":658},"他把瑞它鲁肽描述成让肝脏不堪重负、受到损伤——一场“脂肪肝级联”、一次“肝脏超载”。试验数据显示的恰恰相反。在二期肝脂肪研究里，瑞它鲁肽以剂量依赖的方式减少肝脏脂肪：在第48周，8 mg 组为**−81.7%",{"type":21,"tag":42,"props":660,"children":661},{},[662],{"type":34,"value":663},"，12 mg 组为",{"type":34,"value":665},"−86.0%**，而安慰剂组只有 −4.6%。在最高剂量组里，",{"type":21,"tag":42,"props":667,"children":668},{},[669],{"type":34,"value":670},"约93%的患者肝脂肪降到了5%的阈值以下",{"type":34,"value":672},"——这在医学意义上等于他们的脂肪肝已经恢复了正常（",{"type":21,"tag":91,"props":674,"children":676},{"href":274,"rel":675},[159],[677],{"type":34,"value":278},{"type":34,"value":679},"）。这是迄今为止该药临床开发中报告过的最大幅度的肝脂肪下降之一。瑞它鲁肽不是什么潜伏的肝脏杀手；它恰恰是作为脂肪肝（MASLD）的治疗药物在研发的。在对照试验里，它对肝脏的净效应是强烈的保护——与他所描述的那套级联正好相反。",{"type":21,"tag":123,"props":681,"children":683},{"id":682},"他说对的地方",[684],{"type":34,"value":682},{"type":21,"tag":26,"props":686,"children":687},{},[688],{"type":34,"value":689},"一次公道的事实核查，不能只挑错，也得承认他说对的地方——他的立论背后有两点是站得住脚的。",{"type":21,"tag":26,"props":691,"children":692},{},[693,695,700,702,707,709,714,715,722,724,731],{"type":34,"value":694},"他说对了：你",{"type":21,"tag":42,"props":696,"children":697},{},[698],{"type":34,"value":699},"不应该",{"type":34,"value":701},"为了一个孤立、无症状的脂肪酶升高就慌张停药；这确实符合消化科指南所暗示的做法。他也说对了：在这类药上快速减重会赔上",{"type":21,"tag":42,"props":703,"children":704},{},[705],{"type":34,"value":706},"瘦体重",{"type":34,"value":708},"——减掉的体重里，大约四分之一到接近一半可能是无脂肪质量，其中很大一部分是肌肉（",{"type":21,"tag":91,"props":710,"children":712},{"href":293,"rel":711},[159],[713],{"type":34,"value":297},{"type":34,"value":206},{"type":21,"tag":91,"props":716,"children":719},{"href":717,"rel":718},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11450469\u002F",[159],[720],{"type":34,"value":721},"Tinsley 等，2024",{"type":34,"value":723},"），这正是为什么蛋白质摄入和抗阻训练理应出现在任何一份认真的方案里（",{"type":21,"tag":91,"props":725,"children":728},{"href":726,"rel":727},"https:\u002F\u002Fdiabetesjournals.org\u002Fcare\u002Farticle\u002F47\u002F10\u002F1718\u002F154535\u002F",[159],[729],{"type":34,"value":730},"Locatelli 等，Diabetes Care 2024",{"type":34,"value":732},"）。这些道理都是成立的。问题出在包裹它们的那层外壳上。",{"type":21,"tag":123,"props":734,"children":736},{"id":735},"这套路数",[737],{"type":34,"value":735},{"type":21,"tag":26,"props":739,"children":740},{},[741],{"type":34,"value":742},"在我们看来，这里的结构是一种很眼熟的套路：用真实术语来营造权威感；拼装出一个吓人的“损伤级联”，而按我们对试验数据的解读，证据并不支持它；把别人的声音打上“虚假信息”的标签；然后端出来的解药，是一套付费方案和从作者自家商店买来的肽。我们并不声称掌握他的动机——我们描述的是我们所见到的效果，而其中的商业背景，读者可以自行掂量。",{"type":21,"tag":26,"props":744,"children":745},{},[746],{"type":34,"value":747},"瑞它鲁肽是一款严肃的在研药物，有真实的副作用谱（大多是胃肠道的、剂量依赖的、在加量阶段最严重），关于长期使用和肌肉流失也有真正尚未解答的问题。它值得谨慎对待，也需要一位开处方的临床医生。但它不该被一个卖着“解药”的人，硬扣上一个人为制造的“器官衰竭”叙事。",{"type":21,"tag":749,"props":750,"children":751},"hr",{},[],{"type":21,"tag":123,"props":753,"children":755},{"id":754},"完整的科学图景",[756],{"type":34,"value":754},{"type":21,"tag":26,"props":758,"children":759},{},[760],{"type":34,"value":761},"上面那一节是结论。这一部分是功课：一份带出处的入门读物，讲的是这些药真正在做什么，好让你能自己去判断那些说法，而不是听信任何人的一面之词——无论是我们的还是他的。这部分是故意写得密的。",{"type":21,"tag":123,"props":763,"children":765},{"id":764},"从-nafld-到-masld",[766],{"type":34,"value":767},"从 NAFLD 到 MASLD",{"type":21,"tag":26,"props":769,"children":770},{},[771,773,778,780,787],{"type":34,"value":772},"几十年来，肝脏在没有大量饮酒的情况下堆积脂肪，被称为非酒精性脂肪性肝病（NAFLD）——如今它是地球上最常见的慢性肝病，影响着大约30%到38%的成年人。2023年，一项国际共识把它改名为 ",{"type":21,"tag":42,"props":774,"children":775},{},[776],{"type":34,"value":777},"MASLD——代谢功能障碍相关脂肪性肝病",{"type":34,"value":779},"——为的是把代谢这一根本病因摆到台前，而不是用“它不是什么”来定义这个病（",{"type":21,"tag":91,"props":781,"children":784},{"href":782,"rel":783},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10653297\u002F",[159],[785],{"type":34,"value":786},"Rinella 等，2023",{"type":34,"value":223},{"type":21,"tag":26,"props":789,"children":790},{},[791,793,807],{"type":34,"value":792},"这一进展可以用一个**“多重打击”模型",{"type":21,"tag":42,"props":794,"children":795},{},[796,798,805],{"type":34,"value":797},"来描述：第一击是脂肪在肝细胞里积累，这让肝脏变得容易受到进一步的伤害——氧化应激、线粒体功能障碍、肠肝菌群失调、炎症（",{"type":21,"tag":91,"props":799,"children":802},{"href":800,"rel":801},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26823198\u002F",[159],[803],{"type":34,"value":804},"Buzzetti 等，2016",{"type":34,"value":806},"）。这个谱系从单纯性脂肪变，经过带有炎症和细胞损伤的脂肪性肝炎（MASH），一直发展到纤维化、肝硬化和肝癌。推动这一进展的是",{"type":34,"value":808},"脂毒性**——不是惰性的甘油三酯本身，而是像神经酰胺和二酰甘油这样有毒的脂质中间产物，它们损坏细胞机器，并激活炎症通路。",{"type":21,"tag":123,"props":810,"children":812},{"id":811},"选择性肝脏胰岛素抵抗",[813],{"type":34,"value":811},{"type":21,"tag":26,"props":815,"children":816},{},[817,819,826,827,834],{"type":34,"value":818},"这里最重要的观念之一，主要由 Samuel 和 Shulman 提出，解决了一个悖论：为什么一个糖尿病患者的肝脏无视胰岛素“停止造糖”的信号，却依然听从胰岛素“去造脂肪”的信号（",{"type":21,"tag":91,"props":820,"children":823},{"href":821,"rel":822},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4701542\u002F",[159],[824],{"type":34,"value":825},"Samuel & Shulman，JCI 2016",{"type":34,"value":206},{"type":21,"tag":91,"props":828,"children":831},{"href":829,"rel":830},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC5762395\u002F",[159],[832],{"type":34,"value":833},"Cell Metabolism 2018",{"type":34,"value":223},{"type":21,"tag":26,"props":836,"children":837},{},[838,840,845,847,852,854,861,863,868],{"type":34,"value":839},"机制是这样的：随着脂肪在肝脏里积累，",{"type":21,"tag":42,"props":841,"children":842},{},[843],{"type":34,"value":844},"二酰甘油",{"type":34,"value":846},"堆积起来，激活一种酶（PKCε），它卡住了近端的胰岛素信号。胰岛素再也无法抑制葡萄糖输出——于是血糖上升——但造脂肪的机器却靠着现成的底物和高胰岛素水平继续运转。再加上产生抵抗的脂肪组织把游离脂肪酸直接倾入肝脏，一个脂肪堆积的自我强化循环就此形成。同位素研究给这股流入量标出了具体数字：在脂肪肝患者体内，储存于肝脏的甘油三酯里，约",{"type":21,"tag":42,"props":848,"children":849},{},[850],{"type":34,"value":851},"59%来自循环中的游离脂肪酸",{"type":34,"value":853},"（外周脂解），约26%来自新生脂肪生成，约15%来自饮食（",{"type":21,"tag":91,"props":855,"children":858},{"href":856,"rel":857},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC1087172\u002F",[159],[859],{"type":34,"value":860},"Donnelly 等，JCI 2005",{"type":34,"value":862},"）。这才是那段视频含糊其辞地指向的真实生物学——而这也恰恰是为什么，一种",{"type":21,"tag":30,"props":864,"children":865},{},[866],{"type":34,"value":867},"减少",{"type":34,"value":869},"那股脂肪流入的药物是帮忙而非帮倒忙。",{"type":21,"tag":123,"props":871,"children":873},{"id":872},"胰高血糖素真正做的事以及那个白脂肪误解",[874],{"type":34,"value":875},"胰高血糖素真正做的事——以及那个白脂肪误解",{"type":21,"tag":26,"props":877,"children":878},{},[879,881,886,887,892,893,900,901,907],{"type":34,"value":880},"胰高血糖素长期被塑造成只是胰岛素的对立面，如今则被视为能量和脂质代谢的一个作用广泛的调节者。它的主要靶点是肝脏，在那里它触发葡萄糖释放，而且很重要的是，通过 cAMP\u002FPKA 通路和一个激活肝脏脂肪分解的钙释放机制，",{"type":21,"tag":42,"props":882,"children":883},{},[884],{"type":34,"value":885},"驱动脂肪氧化并抑制新脂肪的合成",{"type":34,"value":240},{"type":21,"tag":91,"props":888,"children":890},{"href":200,"rel":889},[159],[891],{"type":34,"value":204},{"type":34,"value":206},{"type":21,"tag":91,"props":894,"children":897},{"href":895,"rel":896},"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fphysiology\u002Farticles\u002F10.3389\u002Ffphys.2019.00413\u002Ffull",[159],[898],{"type":34,"value":899},"Galsgaard 等，2019",{"type":34,"value":206},{"type":21,"tag":91,"props":902,"children":904},{"href":531,"rel":903},[159],[905],{"type":34,"value":906},"Kajani 等，2024",{"type":34,"value":908},"）。正是这种肝脏“燃脂”，才让药物开发者把一个胰高血糖素信号嫁接到了瑞它鲁肽上。",{"type":21,"tag":26,"props":910,"children":911},{},[912,914,919,921,926,928,933,934,940,942,947],{"type":34,"value":913},"但是——这就是那处要纠正的误解——这个作用是",{"type":21,"tag":42,"props":915,"children":916},{},[917],{"type":34,"value":918},"肝脏的，不是外周的。",{"type":34,"value":920}," 早年的体外实验显示，孤立的脂肪细胞浸在胰高血糖素里时能够分解脂肪，可那浓度比身体所能产生的高出10到100倍。现代研究把这事定了论：把脂肪组织里的胰高血糖素受体敲掉，脂质代谢毫无变化（",{"type":21,"tag":91,"props":922,"children":924},{"href":209,"rel":923},[159],[925],{"type":34,"value":213},{"type":34,"value":927},"）；给人注入生理浓度的胰高血糖素，腹部脂肪的脂解纹丝不动（",{"type":21,"tag":91,"props":929,"children":931},{"href":217,"rel":930},[159],[932],{"type":34,"value":221},{"type":34,"value":206},{"type":21,"tag":91,"props":935,"children":937},{"href":505,"rel":936},[159],[938],{"type":34,"value":939},"Jensen 等，1991",{"type":34,"value":941},"）。含胰高血糖素的药物带来的减重，来自食欲抑制、能量消耗提高，以及",{"type":21,"tag":42,"props":943,"children":944},{},[945],{"type":34,"value":946},"肝脏",{"type":34,"value":948},"脂肪氧化——不是胰高血糖素把你的肚子脂肪化开、再灌满你的器官。",{"type":21,"tag":123,"props":950,"children":952},{"id":951},"多重激动剂的跃迁从司美格鲁肽到瑞它鲁肽",[953],{"type":34,"value":954},"多重激动剂的跃迁：从司美格鲁肽到瑞它鲁肽",{"type":21,"tag":26,"props":956,"children":957},{},[958,960,981,982,989,991,998,1000,1007],{"type":34,"value":959},"肠促胰素类药物是肠道激素的模拟物，经过改造以抵抗快速降解，从而作用更持久。第一波是 GLP-1 单激动剂：司美格鲁肽在其关键性肥胖试验里带来了约",{"type":21,"tag":42,"props":961,"children":962},{},[963,965,979],{"type":34,"value":964},"14.9%",{"type":21,"tag":42,"props":966,"children":967},{},[968,970,977],{"type":34,"value":969},"的平均减重（",{"type":21,"tag":91,"props":971,"children":974},{"href":972,"rel":973},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33567185\u002F",[159],[975],{"type":34,"value":976},"STEP 1，Wilding 等，NEJM 2021",{"type":34,"value":978},"）。接着是 GLP-1\u002FGIP 双激动：替尔泊肽达到了最高",{"type":34,"value":980},"20.9%",{"type":34,"value":240},{"type":21,"tag":91,"props":983,"children":986},{"href":984,"rel":985},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35658024\u002F",[159],[987],{"type":34,"value":988},"SURMOUNT-1，Jastreboff 等，NEJM 2022",{"type":34,"value":990},"）。关于这些激素如何协同作用的生理学，可参见 ",{"type":21,"tag":91,"props":992,"children":995},{"href":993,"rel":994},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39160334\u002F",[159],[996],{"type":34,"value":997},"Holst，Nature Metabolism 2024",{"type":34,"value":999}," 和 ",{"type":21,"tag":91,"props":1001,"children":1004},{"href":1002,"rel":1003},"https:\u002F\u002Fdom-pubs.onlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fdom.14496",[159],[1005],{"type":34,"value":1006},"Nauck 等，2021",{"type":34,"value":173},{"type":21,"tag":26,"props":1009,"children":1010},{},[1011,1013,1018,1020,1027],{"type":34,"value":1012},"瑞它鲁肽（LY3437943）更进一步：一个分子同时作用于 ",{"type":21,"tag":42,"props":1014,"children":1015},{},[1016],{"type":34,"value":1017},"GLP-1、GIP 和胰高血糖素",{"type":34,"value":1019},"三种受体（",{"type":21,"tag":91,"props":1021,"children":1024},{"href":1022,"rel":1023},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04881760",[159],[1025],{"type":34,"value":1026},"试验 NCT04881760",{"type":34,"value":1028},"）。胰高血糖素这一路增加肝脏脂肪氧化和能量消耗；GLP-1 和 GIP 两路则提供食欲抑制、胰岛素支持，以及——最关键的——抵消胰高血糖素升高血糖的倾向。",{"type":21,"tag":26,"props":1030,"children":1031},{},[1032,1034,1039,1041,1048,1049,1055,1057,1062],{"type":34,"value":1033},"关于命名的一点提醒：下面的",{"type":21,"tag":42,"props":1035,"children":1036},{},[1037],{"type":34,"value":1038},"二期",{"type":34,"value":1040},"数据来自 ",{"type":21,"tag":91,"props":1042,"children":1045},{"href":1043,"rel":1044},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37366315\u002F",[159],[1046],{"type":34,"value":1047},"Jastreboff 等，NEJM 2023",{"type":34,"value":999},{"type":21,"tag":91,"props":1050,"children":1052},{"href":274,"rel":1051},[159],[1053],{"type":34,"value":1054},"MASLD 子研究，Sanyal 等，Nature Medicine 2024",{"type":34,"value":1056},"。“TRIUMPH”是后来的",{"type":21,"tag":30,"props":1058,"children":1059},{},[1060],{"type":34,"value":1061},"三期",{"type":34,"value":1063},"项目——所以别让任何人把二期的数字当成 TRIUMPH-1 的结果来呈现。",{"type":21,"tag":26,"props":1065,"children":1066},{},[1067,1072,1074,1080],{"type":21,"tag":42,"props":1068,"children":1069},{},[1070],{"type":34,"value":1071},"第48周的体重变化",{"type":34,"value":1073},"（二期，n=338；",{"type":21,"tag":91,"props":1075,"children":1077},{"href":1043,"rel":1076},[159],[1078],{"type":34,"value":1079},"Jastreboff 等，2023",{"type":34,"value":1081},"）：",{"type":21,"tag":1083,"props":1084,"children":1085},"table",{},[1086,1105],{"type":21,"tag":1087,"props":1088,"children":1089},"thead",{},[1090],{"type":21,"tag":1091,"props":1092,"children":1093},"tr",{},[1094,1100],{"type":21,"tag":1095,"props":1096,"children":1097},"th",{},[1098],{"type":34,"value":1099},"每周剂量",{"type":21,"tag":1095,"props":1101,"children":1102},{},[1103],{"type":34,"value":1104},"平均体重变化",{"type":21,"tag":1106,"props":1107,"children":1108},"tbody",{},[1109,1123,1136,1149,1162],{"type":21,"tag":1091,"props":1110,"children":1111},{},[1112,1118],{"type":21,"tag":1113,"props":1114,"children":1115},"td",{},[1116],{"type":34,"value":1117},"安慰剂",{"type":21,"tag":1113,"props":1119,"children":1120},{},[1121],{"type":34,"value":1122},"−2.1%",{"type":21,"tag":1091,"props":1124,"children":1125},{},[1126,1131],{"type":21,"tag":1113,"props":1127,"children":1128},{},[1129],{"type":34,"value":1130},"瑞它鲁肽 1 mg",{"type":21,"tag":1113,"props":1132,"children":1133},{},[1134],{"type":34,"value":1135},"−8.7%",{"type":21,"tag":1091,"props":1137,"children":1138},{},[1139,1144],{"type":21,"tag":1113,"props":1140,"children":1141},{},[1142],{"type":34,"value":1143},"瑞它鲁肽 4 mg",{"type":21,"tag":1113,"props":1145,"children":1146},{},[1147],{"type":34,"value":1148},"−17.1%",{"type":21,"tag":1091,"props":1150,"children":1151},{},[1152,1157],{"type":21,"tag":1113,"props":1153,"children":1154},{},[1155],{"type":34,"value":1156},"瑞它鲁肽 8 mg",{"type":21,"tag":1113,"props":1158,"children":1159},{},[1160],{"type":34,"value":1161},"−22.8%",{"type":21,"tag":1091,"props":1163,"children":1164},{},[1165,1170],{"type":21,"tag":1113,"props":1166,"children":1167},{},[1168],{"type":34,"value":1169},"瑞它鲁肽 12 mg",{"type":21,"tag":1113,"props":1171,"children":1172},{},[1173],{"type":34,"value":1174},"−24.2%",{"type":21,"tag":26,"props":1176,"children":1177},{},[1178,1183,1185,1191],{"type":21,"tag":42,"props":1179,"children":1180},{},[1181],{"type":34,"value":1182},"第48周的肝脂肪变化",{"type":34,"value":1184},"（MASLD 子研究，n=98；",{"type":21,"tag":91,"props":1186,"children":1188},{"href":274,"rel":1187},[159],[1189],{"type":34,"value":1190},"Sanyal 等，2024",{"type":34,"value":1081},{"type":21,"tag":1083,"props":1193,"children":1194},{},[1195,1215],{"type":21,"tag":1087,"props":1196,"children":1197},{},[1198],{"type":21,"tag":1091,"props":1199,"children":1200},{},[1201,1205,1210],{"type":21,"tag":1095,"props":1202,"children":1203},{},[1204],{"type":34,"value":1099},{"type":21,"tag":1095,"props":1206,"children":1207},{},[1208],{"type":34,"value":1209},"肝脂肪相对变化",{"type":21,"tag":1095,"props":1211,"children":1212},{},[1213],{"type":34,"value":1214},"肝脂肪恢复正常（\u003C5%）",{"type":21,"tag":1106,"props":1216,"children":1217},{},[1218,1235,1252,1269],{"type":21,"tag":1091,"props":1219,"children":1220},{},[1221,1225,1230],{"type":21,"tag":1113,"props":1222,"children":1223},{},[1224],{"type":34,"value":1117},{"type":21,"tag":1113,"props":1226,"children":1227},{},[1228],{"type":34,"value":1229},"−4.6%",{"type":21,"tag":1113,"props":1231,"children":1232},{},[1233],{"type":34,"value":1234},"0%",{"type":21,"tag":1091,"props":1236,"children":1237},{},[1238,1242,1247],{"type":21,"tag":1113,"props":1239,"children":1240},{},[1241],{"type":34,"value":1130},{"type":21,"tag":1113,"props":1243,"children":1244},{},[1245],{"type":34,"value":1246},"−51.3%",{"type":21,"tag":1113,"props":1248,"children":1249},{},[1250],{"type":34,"value":1251},">50%",{"type":21,"tag":1091,"props":1253,"children":1254},{},[1255,1259,1264],{"type":21,"tag":1113,"props":1256,"children":1257},{},[1258],{"type":34,"value":1156},{"type":21,"tag":1113,"props":1260,"children":1261},{},[1262],{"type":34,"value":1263},"−81.7%",{"type":21,"tag":1113,"props":1265,"children":1266},{},[1267],{"type":34,"value":1268},"—",{"type":21,"tag":1091,"props":1270,"children":1271},{},[1272,1276,1281],{"type":21,"tag":1113,"props":1273,"children":1274},{},[1275],{"type":34,"value":1169},{"type":21,"tag":1113,"props":1277,"children":1278},{},[1279],{"type":34,"value":1280},"−86.0%",{"type":21,"tag":1113,"props":1282,"children":1283},{},[1284],{"type":34,"value":1285},"~93%",{"type":21,"tag":26,"props":1287,"children":1288},{},[1289],{"type":34,"value":1290},"不到一年就减掉接近四分之一的体重，达到了以往只有减重手术才能触及的量级——而且在最高剂量下，超过九成患者的脂肪肝恢复了正常。这些正是一个“肝脏超载”叙事不得不无视的数据。",{"type":21,"tag":123,"props":1292,"children":1294},{"id":1293},"胃肠道反应以及麻醉这个问题",[1295],{"type":34,"value":1296},"胃肠道反应，以及麻醉这个问题",{"type":21,"tag":26,"props":1298,"children":1299},{},[1300,1302,1307,1309,1314],{"type":34,"value":1301},"这份疗效的代价，主要落在胃肠道上。胃排空减慢加上脑干的恶心信号，使得",{"type":21,"tag":42,"props":1303,"children":1304},{},[1305],{"type":34,"value":1306},"恶心、呕吐、腹泻和便秘",{"type":34,"value":1308},"成为常见副作用——剂量依赖、在加量阶段最重、通常是一过性的（",{"type":21,"tag":91,"props":1310,"children":1312},{"href":1043,"rel":1311},[159],[1313],{"type":34,"value":1079},{"type":34,"value":1315},"）。缓慢滴定（从低剂量起步）是标准的缓解办法。",{"type":21,"tag":26,"props":1317,"children":1318},{},[1319,1321,1328,1329,1336,1338,1345,1347,1354,1356,1361],{"type":34,"value":1320},"有一个现实后果引发了真正的医学讨论：因为这些药减慢胃排空，食物会在胃里滞留更久，从而增加麻醉前胃内容物残留的可能，带来理论上的误吸风险。荟萃分析确实发现用药者的胃内残留物明显更多（",{"type":21,"tag":91,"props":1322,"children":1325},{"href":1323,"rel":1324},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11264430\u002F",[159],[1326],{"type":34,"value":1327},"do Nascimento 等，2024",{"type":34,"value":206},{"type":21,"tag":91,"props":1330,"children":1333},{"href":1331,"rel":1332},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40133086\u002F",[159],[1334],{"type":34,"value":1335},"Tan 等，2025",{"type":34,"value":1337},"），尽管实际的误吸事件依然罕见（",{"type":21,"tag":91,"props":1339,"children":1342},{"href":1340,"rel":1341},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11651700\u002F",[159],[1343],{"type":34,"value":1344},"Jalleh 等，JCEM 2024",{"type":34,"value":1346},"）。麻醉学会现在建议在择期手术前暂停用药（",{"type":21,"tag":91,"props":1348,"children":1351},{"href":1349,"rel":1350},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37982170\u002F",[159],[1352],{"type":34,"value":1353},"ASA 指南，2024",{"type":34,"value":1355},"）。这是一个合理、且已被充分研究的注意事项——而值得注意的是，这",{"type":21,"tag":30,"props":1357,"children":1358},{},[1359],{"type":34,"value":1360},"恰恰不是",{"type":34,"value":1362},"那段视频所聚焦的那个。",{"type":21,"tag":123,"props":1364,"children":1366},{"id":1365},"胰腺它是怎么工作的以及脂肪酶这个问题",[1367],{"type":34,"value":1368},"胰腺：它是怎么工作的，以及脂肪酶这个问题",{"type":21,"tag":26,"props":1370,"children":1371},{},[1372,1374,1380],{"type":34,"value":1373},"胰腺90%以上是外分泌组织——制造消化酶的腺泡细胞。它们储存无活性的酶前体，一收到信号就释放；而酶在细胞内部提前被激活，才是真正胰腺炎的定义。GLP-1 受体存在于这些腺泡细胞上，所以这些药推动酶释放，属于一种正常的、受体介导的效应（",{"type":21,"tag":91,"props":1375,"children":1377},{"href":571,"rel":1376},[159],[1378],{"type":34,"value":1379},"Hou…Williams 等，2016",{"type":34,"value":223},{"type":21,"tag":26,"props":1382,"children":1383},{},[1384,1386,1391,1393,1399,1401,1405],{"type":34,"value":1385},"这正是为什么用药时轻度的脂肪酶和淀粉酶升高如此常见——也正是为什么它们通常没有意义。它们是被刺激的酶",{"type":21,"tag":30,"props":1387,"children":1388},{},[1389],{"type":34,"value":1390},"渗漏",{"type":34,"value":1392},"，不是组织被破坏。上文的试验证据显示，这些升高并不预示胰腺炎（",{"type":21,"tag":91,"props":1394,"children":1396},{"href":243,"rel":1395},[159],[1397],{"type":34,"value":1398},"Steinberg 等，2017",{"type":34,"value":1400},"），而汇总数据显示，相较于安慰剂并没有额外的胰腺炎风险。确实存在的那点背景风险，是跟着人群走的——肥胖和2型糖尿病人群本身就因为胆结石和高甘油三酯而带有更高的基线胰腺炎风险，与任何药物无关。而正是因为治好了这些诱因，才有可能解释为什么某些数据显示用 GLP-1 治疗后复发",{"type":21,"tag":42,"props":1402,"children":1403},{},[1404],{"type":34,"value":608},{"type":34,"value":173},{"type":21,"tag":123,"props":1407,"children":1409},{"id":1408},"真正的警示瘦体重的流失",[1410],{"type":34,"value":1411},"真正的警示：瘦体重的流失",{"type":21,"tag":26,"props":1413,"children":1414},{},[1415,1417,1422,1424,1429,1430,1435,1437,1443],{"type":34,"value":1416},"如果说有哪一条警告，配得上视频花在幻想中的器官损伤上的那些时长，那就是这一条。在各项肠促胰素试验中，减掉的体重里有相当一部分是",{"type":21,"tag":42,"props":1418,"children":1419},{},[1420],{"type":34,"value":1421},"无脂肪质量",{"type":34,"value":1423},"——大约25%到40%，其中很大一部分是骨骼肌（",{"type":21,"tag":91,"props":1425,"children":1427},{"href":293,"rel":1426},[159],[1428],{"type":34,"value":297},{"type":34,"value":206},{"type":21,"tag":91,"props":1431,"children":1433},{"href":717,"rel":1432},[159],[1434],{"type":34,"value":721},{"type":34,"value":1436},"）。这并不是这些药独有的——任何大幅、快速的减重都会这样——但流失肌肉会降低代谢率（为停药后的反弹埋下伏笔）、降低胰岛素敏感性，并提高老年人的衰弱和跌倒风险。有循证依据的对策一点也不光鲜：在用药的同时，保证充足的蛋白质和渐进式的抗阻训练（",{"type":21,"tag":91,"props":1438,"children":1440},{"href":726,"rel":1439},[159],[1441],{"type":34,"value":1442},"Locatelli 等，2024",{"type":34,"value":223},{"type":21,"tag":123,"props":1445,"children":1447},{"id":1446},"新的前沿免疫代谢与癌症",[1448],{"type":34,"value":1449},"新的前沿：免疫代谢与癌症",{"type":21,"tag":26,"props":1451,"children":1452},{},[1453,1455,1462],{"type":34,"value":1454},"最后，瞥一眼科学正走向何方。肥胖驱动慢性炎症，并让那些对抗肿瘤的免疫细胞在代谢上“精疲力竭”。早期研究提示 GLP-1 类药物或许能部分逆转这一点：在肥胖的肺癌小鼠模型里，一种 GLP-1 激动剂减缓了肿瘤生长，并改善了抗肿瘤的免疫环境——而这种效应只在肥胖动物身上见到（",{"type":21,"tag":91,"props":1456,"children":1459},{"href":1457,"rel":1458},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40857107\u002F",[159],[1460],{"type":34,"value":1461},"Pachimatla…Sanghvi 等，JCI Insight 2025",{"type":34,"value":1463},"）。这还是临床前的、很早期的研究，但它暗示，纠正代谢功能障碍的好处，可能远远超出体重秤上的那个数字。",{"type":21,"tag":123,"props":1465,"children":1467},{"id":1466},"诚实的结论",[1468],{"type":34,"value":1466},{"type":21,"tag":26,"props":1470,"children":1471},{},[1472,1474,1479,1481,1486,1488,1492],{"type":34,"value":1473},"把证据拼到一起，得到的图景与那段视频正好相反。在对照试验里，瑞它鲁肽大幅",{"type":21,"tag":42,"props":1475,"children":1476},{},[1477],{"type":34,"value":1478},"降低",{"type":34,"value":1480},"肝脂肪，",{"type":21,"tag":42,"props":1482,"children":1483},{},[1484],{"type":34,"value":1485},"不会",{"type":34,"value":1487},"提高胰腺炎风险，也",{"type":21,"tag":42,"props":1489,"children":1490},{},[1491],{"type":34,"value":1485},{"type":34,"value":1493},"通过什么胰高血糖素洪流把你的身体脂肪化开。而那些真正需要注意的地方——肌肉流失、胃肠道反应、麻醉这一相互作用，以及一个直白的事实：灰色市场的产品未受监管，可能根本不是标签上写的那个东西——恰恰是一个卖肽给你的商家最没有动力去多谈的。",{"type":21,"tag":26,"props":1495,"children":1496},{},[1497,1499,1504,1506,1512,1514,1520],{"type":34,"value":1498},"如果你正在考虑、或者已经在用这些东西，正确的做法不是一段45分钟的视频加一个结账按钮。而是抽血化验、一位真正的处方医生，以及诚实的预期。要是有什么感觉不对劲，",{"type":21,"tag":42,"props":1500,"children":1501},{},[1502],{"type":34,"value":1503},"在你相信一套由那个在 YouTube 上给你下诊断的人所兜售的方案之前，先去当面找一位你最不那么信不过的医生。",{"type":34,"value":1505}," 想看已发表文献里报告的试验剂量，请见我们的",{"type":21,"tag":91,"props":1507,"children":1509},{"href":1508},"\u002Fglp1\u002Fretatrutide",[1510],{"type":34,"value":1511},"瑞它鲁肽参考页",{"type":34,"value":1513},"；想先弄懂这一类药，就从",{"type":21,"tag":91,"props":1515,"children":1517},{"href":1516},"\u002Fwhat-are-peptides",[1518],{"type":34,"value":1519},"什么是肽",{"type":34,"value":1521},"开始。",{"type":21,"tag":123,"props":1523,"children":1525},{"id":1524},"参考文献",[1526],{"type":34,"value":1524},{"type":21,"tag":1528,"props":1529,"children":1530},"ol",{},[1531,1565,1597,1614,1636,1658,1682,1706,1729,1751,1774,1797,1822,1852,1875,1897,1919,1941,1963,1985,2007,2030,2052,2074,2096,2118,2139,2161,2183,2204,2226,2248,2266,2282,2299,2316],{"type":21,"tag":138,"props":1532,"children":1533},{},[1534,1536,1541,1543,1548,1550,1556,1558],{"type":34,"value":1535},"Jastreboff AM, Kaplan LM, Frías JP, et al. ",{"type":21,"tag":42,"props":1537,"children":1538},{},[1539],{"type":34,"value":1540},"Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.",{"type":34,"value":1542}," ",{"type":21,"tag":30,"props":1544,"children":1545},{},[1546],{"type":34,"value":1547},"N Engl J Med",{"type":34,"value":1549}," 2023. ",{"type":21,"tag":91,"props":1551,"children":1553},{"href":1043,"rel":1552},[159],[1554],{"type":34,"value":1555},"PubMed",{"type":34,"value":1557}," · ",{"type":21,"tag":91,"props":1559,"children":1562},{"href":1560,"rel":1561},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2301972",[159],[1563],{"type":34,"value":1564},"NEJM",{"type":21,"tag":138,"props":1566,"children":1567},{},[1568,1570,1575,1576,1581,1583,1589,1590],{"type":34,"value":1569},"Sanyal AJ, et al. ",{"type":21,"tag":42,"props":1571,"children":1572},{},[1573],{"type":34,"value":1574},"Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1577,"children":1578},{},[1579],{"type":34,"value":1580},"Nature Medicine",{"type":34,"value":1582}," 2024. ",{"type":21,"tag":91,"props":1584,"children":1586},{"href":274,"rel":1585},[159],[1587],{"type":34,"value":1588},"PMC full text",{"type":34,"value":1557},{"type":21,"tag":91,"props":1591,"children":1594},{"href":1592,"rel":1593},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2",[159],[1595],{"type":34,"value":1596},"Nature",{"type":21,"tag":138,"props":1598,"children":1599},{},[1600,1602,1607,1608],{"type":34,"value":1601},"Phase-2 retatrutide obesity trial registration. ",{"type":21,"tag":30,"props":1603,"children":1604},{},[1605],{"type":34,"value":1606},"ClinicalTrials.gov",{"type":34,"value":1542},{"type":21,"tag":91,"props":1609,"children":1611},{"href":1022,"rel":1610},[159],[1612],{"type":34,"value":1613},"NCT04881760",{"type":21,"tag":138,"props":1615,"children":1616},{},[1617,1619,1624,1625,1629,1631],{"type":34,"value":1618},"Perry RJ, et al. ",{"type":21,"tag":42,"props":1620,"children":1621},{},[1622],{"type":34,"value":1623},"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1626,"children":1627},{},[1628],{"type":34,"value":1596},{"type":34,"value":1630}," 2020. ",{"type":21,"tag":91,"props":1632,"children":1634},{"href":200,"rel":1633},[159],[1635],{"type":34,"value":1555},{"type":21,"tag":138,"props":1637,"children":1638},{},[1639,1641,1646,1647,1652,1653],{"type":34,"value":1640},"Kajani S, et al. ",{"type":21,"tag":42,"props":1642,"children":1643},{},[1644],{"type":34,"value":1645},"Hepatic glucagon action: beyond glucose mobilization.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1648,"children":1649},{},[1650],{"type":34,"value":1651},"Physiological Reviews",{"type":34,"value":1582},{"type":21,"tag":91,"props":1654,"children":1656},{"href":531,"rel":1655},[159],[1657],{"type":34,"value":1555},{"type":21,"tag":138,"props":1659,"children":1660},{},[1661,1663,1668,1669,1674,1676],{"type":34,"value":1662},"Galsgaard KD, et al. ",{"type":21,"tag":42,"props":1664,"children":1665},{},[1666],{"type":34,"value":1667},"Glucagon Receptor Signaling and Lipid Metabolism.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1670,"children":1671},{},[1672],{"type":34,"value":1673},"Front Physiol",{"type":34,"value":1675}," 2019. ",{"type":21,"tag":91,"props":1677,"children":1679},{"href":895,"rel":1678},[159],[1680],{"type":34,"value":1681},"Full text",{"type":21,"tag":138,"props":1683,"children":1684},{},[1685,1687,1692,1693,1698,1700],{"type":34,"value":1686},"Vasileva A, et al. ",{"type":21,"tag":42,"props":1688,"children":1689},{},[1690],{"type":34,"value":1691},"Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1694,"children":1695},{},[1696],{"type":34,"value":1697},"Am J Physiol Endocrinol Metab",{"type":34,"value":1699}," 2022. ",{"type":21,"tag":91,"props":1701,"children":1703},{"href":209,"rel":1702},[159],[1704],{"type":34,"value":1705},"PMC",{"type":21,"tag":138,"props":1707,"children":1708},{},[1709,1711,1716,1717,1722,1724],{"type":34,"value":1710},"Gravholt CH, et al. ",{"type":21,"tag":42,"props":1712,"children":1713},{},[1714],{"type":34,"value":1715},"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1718,"children":1719},{},[1720],{"type":34,"value":1721},"JCEM",{"type":34,"value":1723}," 2001. ",{"type":21,"tag":91,"props":1725,"children":1727},{"href":217,"rel":1726},[159],[1728],{"type":34,"value":1555},{"type":21,"tag":138,"props":1730,"children":1731},{},[1732,1734,1739,1740,1744,1746],{"type":34,"value":1733},"Jensen MD, et al. ",{"type":21,"tag":42,"props":1735,"children":1736},{},[1737],{"type":34,"value":1738},"Effects of glucagon on free fatty acid metabolism in humans.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1741,"children":1742},{},[1743],{"type":34,"value":1721},{"type":34,"value":1745}," 1991. ",{"type":21,"tag":91,"props":1747,"children":1749},{"href":505,"rel":1748},[159],[1750],{"type":34,"value":1555},{"type":21,"tag":138,"props":1752,"children":1753},{},[1754,1756,1761,1762,1767,1769],{"type":34,"value":1755},"Hou Y, Ernst SA, Heidenreich K, Williams JA. ",{"type":21,"tag":42,"props":1757,"children":1758},{},[1759],{"type":34,"value":1760},"GLP-1 receptor is present in pancreatic acinar cells and regulates amylase secretion.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1763,"children":1764},{},[1765],{"type":34,"value":1766},"Am J Physiol Gastrointest Liver Physiol",{"type":34,"value":1768}," 2016. ",{"type":21,"tag":91,"props":1770,"children":1772},{"href":571,"rel":1771},[159],[1773],{"type":34,"value":1705},{"type":21,"tag":138,"props":1775,"children":1776},{},[1777,1779,1784,1785,1790,1792],{"type":34,"value":1778},"Steinberg WM, et al. ",{"type":21,"tag":42,"props":1780,"children":1781},{},[1782],{"type":34,"value":1783},"Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide (LEADER).",{"type":34,"value":1542},{"type":21,"tag":30,"props":1786,"children":1787},{},[1788],{"type":34,"value":1789},"Diabetes Care",{"type":34,"value":1791}," 2017. ",{"type":21,"tag":91,"props":1793,"children":1795},{"href":243,"rel":1794},[159],[1796],{"type":34,"value":1555},{"type":21,"tag":138,"props":1798,"children":1799},{},[1800,1802,1807,1809,1814,1816],{"type":34,"value":1801},"GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review. ",{"type":21,"tag":30,"props":1803,"children":1804},{},[1805],{"type":34,"value":1806},"medRxiv",{"type":34,"value":1808}," 2026 (",{"type":21,"tag":42,"props":1810,"children":1811},{},[1812],{"type":34,"value":1813},"预印本，尚未经过同行评审",{"type":34,"value":1815},"). ",{"type":21,"tag":91,"props":1817,"children":1819},{"href":597,"rel":1818},[159],[1820],{"type":34,"value":1821},"Preprint",{"type":21,"tag":138,"props":1823,"children":1824},{},[1825,1827,1832,1833,1838,1840,1845,1846],{"type":34,"value":1826},"Nassar M, et al. ",{"type":21,"tag":42,"props":1828,"children":1829},{},[1830],{"type":34,"value":1831},"GLP-1 medications may lower risk of recurrent acute pancreatitis.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1834,"children":1835},{},[1836],{"type":34,"value":1837},"ENDO 2024",{"type":34,"value":1839}," (",{"type":21,"tag":42,"props":1841,"children":1842},{},[1843],{"type":34,"value":1844},"会议摘要",{"type":34,"value":1815},{"type":21,"tag":91,"props":1847,"children":1849},{"href":612,"rel":1848},[159],[1850],{"type":34,"value":1851},"Press release",{"type":21,"tag":138,"props":1853,"children":1854},{},[1855,1857,1862,1863,1868,1870],{"type":34,"value":1856},"Banks PA, et al. ",{"type":21,"tag":42,"props":1858,"children":1859},{},[1860],{"type":34,"value":1861},"Classification of acute pancreatitis — 2012: revision of the Atlanta classification.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1864,"children":1865},{},[1866],{"type":34,"value":1867},"Gut",{"type":34,"value":1869}," 2013. ",{"type":21,"tag":91,"props":1871,"children":1873},{"href":628,"rel":1872},[159],[1874],{"type":34,"value":1555},{"type":21,"tag":138,"props":1876,"children":1877},{},[1878,1880,1885,1886,1891,1892],{"type":34,"value":1879},"Rinella ME, et al. ",{"type":21,"tag":42,"props":1881,"children":1882},{},[1883],{"type":34,"value":1884},"A multisociety Delphi consensus on new fatty liver disease nomenclature (MASLD).",{"type":34,"value":1542},{"type":21,"tag":30,"props":1887,"children":1888},{},[1889],{"type":34,"value":1890},"Hepatology \u002F J Hepatol",{"type":34,"value":1549},{"type":21,"tag":91,"props":1893,"children":1895},{"href":782,"rel":1894},[159],[1896],{"type":34,"value":1705},{"type":21,"tag":138,"props":1898,"children":1899},{},[1900,1902,1907,1908,1913,1914],{"type":34,"value":1901},"Samuel VT, Shulman GI. ",{"type":21,"tag":42,"props":1903,"children":1904},{},[1905],{"type":34,"value":1906},"The pathogenesis of insulin resistance.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1909,"children":1910},{},[1911],{"type":34,"value":1912},"J Clin Invest",{"type":34,"value":1768},{"type":21,"tag":91,"props":1915,"children":1917},{"href":821,"rel":1916},[159],[1918],{"type":34,"value":1705},{"type":21,"tag":138,"props":1920,"children":1921},{},[1922,1923,1928,1929,1934,1936],{"type":34,"value":1901},{"type":21,"tag":42,"props":1924,"children":1925},{},[1926],{"type":34,"value":1927},"NAFLD as a Nexus of Metabolic and Hepatic Diseases.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1930,"children":1931},{},[1932],{"type":34,"value":1933},"Cell Metabolism",{"type":34,"value":1935}," 2018. ",{"type":21,"tag":91,"props":1937,"children":1939},{"href":829,"rel":1938},[159],[1940],{"type":34,"value":1705},{"type":21,"tag":138,"props":1942,"children":1943},{},[1944,1946,1951,1952,1957,1958],{"type":34,"value":1945},"Buzzetti E, Pinzani M, Tsochatzis EA. ",{"type":21,"tag":42,"props":1947,"children":1948},{},[1949],{"type":34,"value":1950},"The multiple-hit pathogenesis of NAFLD.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1953,"children":1954},{},[1955],{"type":34,"value":1956},"Metabolism",{"type":34,"value":1768},{"type":21,"tag":91,"props":1959,"children":1961},{"href":800,"rel":1960},[159],[1962],{"type":34,"value":1555},{"type":21,"tag":138,"props":1964,"children":1965},{},[1966,1968,1973,1974,1978,1980],{"type":34,"value":1967},"Donnelly KL, et al. ",{"type":21,"tag":42,"props":1969,"children":1970},{},[1971],{"type":34,"value":1972},"Sources of fatty acids stored in liver and secreted via lipoproteins in NAFLD.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1975,"children":1976},{},[1977],{"type":34,"value":1912},{"type":34,"value":1979}," 2005. ",{"type":21,"tag":91,"props":1981,"children":1983},{"href":856,"rel":1982},[159],[1984],{"type":34,"value":1705},{"type":21,"tag":138,"props":1986,"children":1987},{},[1988,1990,1995,1996,2000,2001],{"type":34,"value":1989},"Locatelli JC, et al. ",{"type":21,"tag":42,"props":1991,"children":1992},{},[1993],{"type":34,"value":1994},"Incretin-Based Weight Loss and Resistance Exercise.",{"type":34,"value":1542},{"type":21,"tag":30,"props":1997,"children":1998},{},[1999],{"type":34,"value":1789},{"type":34,"value":1582},{"type":21,"tag":91,"props":2002,"children":2004},{"href":726,"rel":2003},[159],[2005],{"type":34,"value":2006},"Article",{"type":21,"tag":138,"props":2008,"children":2009},{},[2010,2012,2017,2018,2023,2025],{"type":34,"value":2011},"Koceva A, et al. ",{"type":21,"tag":42,"props":2013,"children":2014},{},[2015],{"type":34,"value":2016},"Impact of Incretin-Based Therapy on Skeletal Muscle Health.",{"type":34,"value":1542},{"type":21,"tag":30,"props":2019,"children":2020},{},[2021],{"type":34,"value":2022},"Medicina",{"type":34,"value":2024}," 2025. ",{"type":21,"tag":91,"props":2026,"children":2028},{"href":293,"rel":2027},[159],[2029],{"type":34,"value":1705},{"type":21,"tag":138,"props":2031,"children":2032},{},[2033,2035,2040,2041,2046,2047],{"type":34,"value":2034},"Tinsley GM, et al. ",{"type":21,"tag":42,"props":2036,"children":2037},{},[2038],{"type":34,"value":2039},"Body Composition Principles for Fat-Free and Skeletal Muscle Mass Changes.",{"type":34,"value":1542},{"type":21,"tag":30,"props":2042,"children":2043},{},[2044],{"type":34,"value":2045},"J Endocr Soc",{"type":34,"value":1582},{"type":21,"tag":91,"props":2048,"children":2050},{"href":717,"rel":2049},[159],[2051],{"type":34,"value":1705},{"type":21,"tag":138,"props":2053,"children":2054},{},[2055,2057,2062,2063,2068,2069],{"type":34,"value":2056},"do Nascimento TS, et al. ",{"type":21,"tag":42,"props":2058,"children":2059},{},[2060],{"type":34,"value":2061},"GLP-1 receptor agonists and residual gastric content (perioperative).",{"type":34,"value":1542},{"type":21,"tag":30,"props":2064,"children":2065},{},[2066],{"type":34,"value":2067},"Perioper Med",{"type":34,"value":1582},{"type":21,"tag":91,"props":2070,"children":2072},{"href":1323,"rel":2071},[159],[2073],{"type":34,"value":1705},{"type":21,"tag":138,"props":2075,"children":2076},{},[2077,2079,2084,2085,2090,2091],{"type":34,"value":2078},"Tan Y, et al. ",{"type":21,"tag":42,"props":2080,"children":2081},{},[2082],{"type":34,"value":2083},"GLP-1 receptor agonists increase residual gastric content and aspiration risk.",{"type":34,"value":1542},{"type":21,"tag":30,"props":2086,"children":2087},{},[2088],{"type":34,"value":2089},"Dig Liver Dis",{"type":34,"value":2024},{"type":21,"tag":91,"props":2092,"children":2094},{"href":1331,"rel":2093},[159],[2095],{"type":34,"value":1555},{"type":21,"tag":138,"props":2097,"children":2098},{},[2099,2101,2106,2107,2112,2113],{"type":34,"value":2100},"Ushakumari DS, et al. ",{"type":21,"tag":42,"props":2102,"children":2103},{},[2104],{"type":34,"value":2105},"ASA Consensus-based Guidance on Preoperative Management of GLP-1 RAs.",{"type":34,"value":1542},{"type":21,"tag":30,"props":2108,"children":2109},{},[2110],{"type":34,"value":2111},"Anesthesiology",{"type":34,"value":1582},{"type":21,"tag":91,"props":2114,"children":2116},{"href":1349,"rel":2115},[159],[2117],{"type":34,"value":1555},{"type":21,"tag":138,"props":2119,"children":2120},{},[2121,2123,2128,2129,2133,2134],{"type":34,"value":2122},"Jalleh RJ, et al. ",{"type":21,"tag":42,"props":2124,"children":2125},{},[2126],{"type":34,"value":2127},"Clinical Consequences of Delayed Gastric Emptying With GLP-1 RAs.",{"type":34,"value":1542},{"type":21,"tag":30,"props":2130,"children":2131},{},[2132],{"type":34,"value":1721},{"type":34,"value":1582},{"type":21,"tag":91,"props":2135,"children":2137},{"href":1340,"rel":2136},[159],[2138],{"type":34,"value":1705},{"type":21,"tag":138,"props":2140,"children":2141},{},[2142,2144,2149,2150,2155,2156],{"type":34,"value":2143},"Pachimatla AG, … Sanghvi VR, et al. ",{"type":21,"tag":42,"props":2145,"children":2146},{},[2147],{"type":34,"value":2148},"GLP-1 receptor agonism improves lung cancer outcomes and tumor immunity (obese models).",{"type":34,"value":1542},{"type":21,"tag":30,"props":2151,"children":2152},{},[2153],{"type":34,"value":2154},"JCI Insight",{"type":34,"value":2024},{"type":21,"tag":91,"props":2157,"children":2159},{"href":1457,"rel":2158},[159],[2160],{"type":34,"value":1555},{"type":21,"tag":138,"props":2162,"children":2163},{},[2164,2166,2171,2172,2176,2178],{"type":34,"value":2165},"Wilding JPH, et al. ",{"type":21,"tag":42,"props":2167,"children":2168},{},[2169],{"type":34,"value":2170},"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).",{"type":34,"value":1542},{"type":21,"tag":30,"props":2173,"children":2174},{},[2175],{"type":34,"value":1547},{"type":34,"value":2177}," 2021. ",{"type":21,"tag":91,"props":2179,"children":2181},{"href":972,"rel":2180},[159],[2182],{"type":34,"value":1555},{"type":21,"tag":138,"props":2184,"children":2185},{},[2186,2188,2193,2194,2198,2199],{"type":34,"value":2187},"Jastreboff AM, et al. ",{"type":21,"tag":42,"props":2189,"children":2190},{},[2191],{"type":34,"value":2192},"Tirzepatide Once Weekly for Obesity (SURMOUNT-1).",{"type":34,"value":1542},{"type":21,"tag":30,"props":2195,"children":2196},{},[2197],{"type":34,"value":1547},{"type":34,"value":1699},{"type":21,"tag":91,"props":2200,"children":2202},{"href":984,"rel":2201},[159],[2203],{"type":34,"value":1555},{"type":21,"tag":138,"props":2205,"children":2206},{},[2207,2209,2214,2215,2220,2221],{"type":34,"value":2208},"Holst JJ. ",{"type":21,"tag":42,"props":2210,"children":2211},{},[2212],{"type":34,"value":2213},"GLP-1 physiology in obesity and incretin-based drugs.",{"type":34,"value":1542},{"type":21,"tag":30,"props":2216,"children":2217},{},[2218],{"type":34,"value":2219},"Nature Metabolism",{"type":34,"value":1582},{"type":21,"tag":91,"props":2222,"children":2224},{"href":993,"rel":2223},[159],[2225],{"type":34,"value":1555},{"type":21,"tag":138,"props":2227,"children":2228},{},[2229,2231,2236,2237,2242,2243],{"type":34,"value":2230},"Nauck MA, et al. ",{"type":21,"tag":42,"props":2232,"children":2233},{},[2234],{"type":34,"value":2235},"The evolving story of incretins (GIP and GLP-1).",{"type":34,"value":1542},{"type":21,"tag":30,"props":2238,"children":2239},{},[2240],{"type":34,"value":2241},"Diabetes Obes Metab",{"type":34,"value":2177},{"type":21,"tag":91,"props":2244,"children":2246},{"href":1002,"rel":2245},[159],[2247],{"type":34,"value":2006},{"type":21,"tag":138,"props":2249,"children":2250},{},[2251,2253,2258,2260],{"type":34,"value":2252},"California Board of Chiropractic Examiners. ",{"type":21,"tag":42,"props":2254,"children":2255},{},[2256],{"type":34,"value":2257},"Meeting materials, 29 Oct 2020",{"type":34,"value":2259}," (licence DC 29377, revoked 8 Jul 2020). ",{"type":21,"tag":91,"props":2261,"children":2263},{"href":157,"rel":2262},[159],[2264],{"type":34,"value":2265},"PDF",{"type":21,"tag":138,"props":2267,"children":2268},{},[2269,2270,2275,2276],{"type":34,"value":2252},{"type":21,"tag":42,"props":2271,"children":2272},{},[2273],{"type":34,"value":2274},"Final Disciplinary Actions.",{"type":34,"value":1542},{"type":21,"tag":91,"props":2277,"children":2279},{"href":365,"rel":2278},[159],[2280],{"type":34,"value":2281},"Page",{"type":21,"tag":138,"props":2283,"children":2284},{},[2285,2287,2292,2293],{"type":34,"value":2286},"California Department of Consumer Affairs. ",{"type":21,"tag":42,"props":2288,"children":2289},{},[2290],{"type":34,"value":2291},"License Search.",{"type":34,"value":1542},{"type":21,"tag":91,"props":2294,"children":2296},{"href":374,"rel":2295},[159],[2297],{"type":34,"value":2298},"Lookup",{"type":21,"tag":138,"props":2300,"children":2301},{},[2302,2304,2309,2310],{"type":34,"value":2303},"EliteBiogenix. ",{"type":21,"tag":42,"props":2305,"children":2306},{},[2307],{"type":34,"value":2308},"Research peptides and SARMs vendor (in-vitro research only).",{"type":34,"value":1542},{"type":21,"tag":91,"props":2311,"children":2313},{"href":167,"rel":2312},[159],[2314],{"type":34,"value":2315},"Site",{"type":21,"tag":138,"props":2317,"children":2318},{},[2319,2321,2326,2327,2332,2333],{"type":34,"value":2320},"Bachmeyer T. ",{"type":21,"tag":42,"props":2322,"children":2323},{},[2324],{"type":34,"value":2325},"\"Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More?\"",{"type":34,"value":1542},{"type":21,"tag":30,"props":2328,"children":2329},{},[2330],{"type":34,"value":2331},"YouTube.",{"type":34,"value":1542},{"type":21,"tag":91,"props":2334,"children":2337},{"href":2335,"rel":2336},"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gb-XEtsMr-w",[159],[2338],{"type":34,"value":2339},"Video",{"title":7,"searchDepth":2341,"depth":2341,"links":2342},2,[2343,2344,2345,2346,2347,2348,2349,2350,2351,2352,2353,2354,2355,2356,2357,2358,2359,2360,2361],{"id":125,"depth":2341,"text":125},{"id":313,"depth":2341,"text":313},{"id":402,"depth":2341,"text":405},{"id":459,"depth":2341,"text":462},{"id":540,"depth":2341,"text":543},{"id":637,"depth":2341,"text":640},{"id":682,"depth":2341,"text":682},{"id":735,"depth":2341,"text":735},{"id":754,"depth":2341,"text":754},{"id":764,"depth":2341,"text":767},{"id":811,"depth":2341,"text":811},{"id":872,"depth":2341,"text":875},{"id":951,"depth":2341,"text":954},{"id":1293,"depth":2341,"text":1296},{"id":1365,"depth":2341,"text":1368},{"id":1408,"depth":2341,"text":1411},{"id":1446,"depth":2341,"text":1449},{"id":1466,"depth":2341,"text":1466},{"id":1524,"depth":2341,"text":1524},"markdown","content:blog:zh:retatrutide-liver-damage-myths.md","content","blog\u002Fzh\u002Fretatrutide-liver-damage-myths.md","blog\u002Fzh\u002Fretatrutide-liver-damage-myths","md"]